publication date: Dec. 18, 2010

In this issue: 

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.

Appreciation: Quack-Buster Saul Green Used Science to Debunk Alternative Medicine Claims.

Download (PDF 393KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.